We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
-4.1%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$353M
AUM Growth
+$76.3M
Cap. Flow
+$120M
Cap. Flow %
33.96%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$108M
2
VTYX
Ventyx Biosciences
VTYX
+$11.6M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$101K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
1
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$115M 32.47%
+5,158,162
New +$108M
PHVS icon
2
Pharvaris
PHVS
$2.39B
$89M 25.24%
4,264,672
– –
ALXO icon
3
ALX Oncology
ALXO
$273M
$46.6M 13.2%
9,699,925
– –
SLRN
4
DELISTED
ACELYRIN
SLRN
$39.2M 11.11%
3,852,470
-4,760
-0.1% -$101K
HRMY icon
5
Harmony Biosciences
HRMY
$2.04B
$33.9M 9.62%
1,035,396
– –
VTYX
6
DELISTED
Ventyx Biosciences
VTYX
$26.4M 7.47%
758,800
+334,768
+79% +$11.6M
ELEV
7
DELISTED
Elevation Oncology
ELEV
$1.93M 0.55%
2,914,255
– –
IMPL
8
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$1.19M 0.34%
2,759,791
– –

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q3 2023 Portfolio in Review

As of Q3 2023, venBio Partners held 8 positions worth $353M, up 28% from $276M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $120M of net new capital in Q3 2023, opening 1 new position and adding to 1 existing holding. Its largest new stake was RayzeBio, Inc. Common Stock: 5,158,162 shares worth $115M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ACELYRIN, an estimated $101K trimmed.

  • venBio Partners's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 5,158,162 shares worth $115M.
  • venBio Partners added most to Ventyx Biosciences in Q3 2023, an estimated $11.6M increase.
  • venBio Partners's biggest Q3 2023 reduction was ACELYRIN, cutting an estimated $101K.
  • venBio Partners's ten largest holdings make up 100% of its $353M portfolio in Q3 2023.
  • venBio Partners opened 1 new position and closed 0 in Q3 2023.
  • venBio Partners's portfolio value rose 28% quarter-over-quarter to $353M.

Based on venBio Partners's 13F filing for Q3 2023, filed 14 Nov 2023.